IP Library Granted Patent US 11,065,337
Granted Patent B2
US 11,065,337 · App. 16/060,075 · Granted Jul 20, 2021

Complex coacervate for controlled release and related methods

Inventors: Eric M. Jeffries (West New York, NJ); Yadong Wang (Bradford Woods, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
A61K47/58A61K9/0019A61K9/06A61K9/08A61K9/10A61K31/727A61K38/18A61K38/1825A61K38/20A61K38/208A61K38/2066A61K38/21A61K47/34A61K47/36A61K47/61A61P9/10A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,065,337
App. No.
16/060,075
Granted
Jul 20, 2021
Kind
B2
Abstract

Provided herein are coacervate compositions including cytokines, and methods of making and using the same. The coacervate can be formed by the mixing of an active agent, such as a drug or protein with the polyanion, such as heparin or heparan sulfate, and a custom-made polycation (e.g., PEAD or PELD). The coacervates can be used in the treatment of diseases and disorders where targeted treatment is desired, for example in treatment of cancers.

Claims (13)

1. A composition comprising a complex or coacervate of a polycationic polymer, a polyanionic polymer, FGF2, and IL-10 in amounts effective to reduce myocardial fibrosis in a patient following a myocardial infarction.

2. The composition of claim 1 , wherein the polyanionic polymer is a heparin or heparan sulfate.

3. The composition of claim 1 , wherein the polycationic polymer is a copolymer comprising a polyester backbone comprising a copolymer of ethylene glycol diglyceride and either aspartic acid or glutamic acid, and pendant arginine groups.

4. The composition of claim 3 , wherein the polycationic polymer has a polydispersity index of less than 3.0.

5. The composition of claim 1 , in which the ratio of the polycationic polymer to the polyanionic polymer in the composition results in a neutral charge.

6. The composition of claim 1 , embedded in a hydrogel.

7. A method of delivering an interferon to a patient in need thereof, comprising administering the composition of claim 1 to the patient.

8. A method of treating a myocardial infarct in a patient, comprising, delivering to the myocardium at or adjacent to the infarct the composition of claim 1 in an amount effective to reduce myocardial fibrosis in the patient.

9. The composition of claim 1 , in which the ratio of the polycationic polymer to the polyanionic polymer in the composition results in a negative charge.

10. The composition of claim 1 , in which the ratio of the polycationic polymer to the polyanionic polymer in the composition results in a positive charge.

11. The composition of claim 1 , wherein the polycationic polymer is a copolymer comprising a polyester backbone comprising a copolymer of ethylene glycol diglyceride and either aspartic acid or glutamic acid, and pendant lysine groups.

12. The composition of claim 1 , wherein the polycationic polymer is poly(ethylene arginylaspartate diglyceride).

13. The composition of claim 1 , wherein the polycationic polymer is poly(ethylene lysinlyaspartate diglyceride).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2020
From: JEFFRIES, ERIC M.; WANG, YADONG
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 053452/0645 →
CONFIRMATORY LICENSE Recorded May 22, 2019
From: UNIVERSITY OF PITTSBURGH
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 050278/0840 →
Continuity (2)
Provisional Application 62266896 · Dec 14, 2015
Related Publication 20180360976A1 · Dec 20, 2018